Yesterday, Montea reported results that had an initial negative market reaction. After the call, the management and chairman Dirk De Pauw were available for a sit-down lunch to give more colour. The Q&A session centered on the pace of the development pipeline. Montea removed its project table as it believes it hurts their negotiating capacity. Now, it just reports an expected GLA of 236k sqm that will be completed over the next 2 years. The reason why it takes longer to develop the landbank is a...
Company comments AB InBev: Little to disappoint Adyen: 2H25 results – mixed results, soft guidance CVC Capital Partners: Executing well dsm-firmenich: Messy results Fagron: Beat on all lines, confident FY26 outlook to drive c.5% consensus EBITDA upgrade Flow Traders: EMEA saves the day KBC: Good results, opening up “jaws” further to 2028 Kinepolis: Canadian peer Cineplex 4Q25 results below consensus, January 2026 box office revenue up MICC: FX headwind leads to a 50bp margin miss in FY25 Montea:...
Montea reported FY25 results in line with its guidance. EPRA earnings grew 18% to €112.8m and EPRA EPS +8% at €4.90 vs. €5.00 expected(KBCS). Net rental income grew 21% yoy, driven by the NL Intergamma completion to €139.8m. We anticipated a higher NRI of 143.3m, mainly driven by more acquisitions. The portfolio maintained a high occupancy of 99.8% and achieved like-for-like rental growth of 3.2% (2.9% indexing). The cost of debt declined to 2.1% vs. 2.3% FY24. Montea's financial position remain...
We updated our model (New “Accumulate”, New € 5.1 TP) after Biotalys plans a strategic refocus, concentrating resources on its top-priority biofungicide programs. Early-stage activities will be suspended and the organization downsized to cut costs while they claim “protecting long-term platform value”. The shift prioritizes Evoca NG, BioFun-6, and already partnered programs with the Gates Foundation and Syngenta. These measures aim to reduce cash burn by €20m through 2028 and strengthen commerci...
We will update our model (from “Buy” to “under review”) after Biotalys plans a strategic refocus, concentrating resources on its top-priority biofungicide programs. Early-stage activities will be suspended and the organization downsized to cut costs while protecting long-term platform value. The shift prioritizes EVOCA NG, BioFun-6, and already partnered programs with the Gates Foundation and Syngenta. These measures aim to reduce cash burn by €20m through 2028 and strengthen commercialization r...
Disclosure of transparency notification Article 14, paragraph 1 of the law of 2 May 2007 on disclosure of major shareholdings Ascencio has received a transparency declaration from Carl, Eric and John Mestdagh as well as the controlled companies informing her that they now jointly hold 787,418 voting rights in the Company. They jointly declare a 11.94% shareholding. Crossing of the 5% threshold upwards by Carl Mestdagh and CMHC SRL. Attachment
Publication relative à une notification de transparence Article 14, Alinéa 1 de la loi du 2 mai 2007 relative à la publicité des participations importantes Ascencio a reçu une notification de transparence de la part de Carl, Eric et John Mestdagh ainsi que les sociétés liées l’informant qu’ils détiennent désormais conjointement 787.418 droits de vote de la Société. Ils déclarent de concert un actionnariat à 11,94%. Franchissement du seuil de 5% à la hausse par Carl Mestdagh et CMHC SRL. Pièce jointe
Openbaarmaking over een transparantieverklaring Artikel 4,1E lid van de Wet van 2 mei 2007 op de openbaarmaking van belangrijke deelnemingen Ascencio heeft een transparantieverklaring van Carl, Eric en John Mestdagh en de verbonden ondernemingen die hem medelen dat zij nu gezamenlijk 787.418 stemrechten van de Vennootschap bezitten. Ze verklaren gezamenlijk een aandelenbezit van 11,94%. Overschrijding van de drempel van 5% naar boven door Carl Mestdagh en CMHC SRL. Bijlage
Flow Traders: Preview 4Q25 / Kinepolis: January reassures with US box office revenue up 14% YoY, France visitors up 15% YoY / Lotus Bakeries: Peer Mondelez 4Q25 results / MICC: Peer Mondelez 4Q25 results / RELX / Wolters Kluwer: Anthropic moves into Legal / Signify: Analyst lunch highlights / TomTom: 4Q25 results, bridging a gap / UCB: Evenity sales exceeded US$2.1bn in FY25 as per Amgen
Ordinary General Meeting of 30 January 2026 - Result The Ordinary General Meeting of Shareholders of 30 January 2026 approved all the proposed resolutions on the agenda, which mainly concerned the financial statements of Ascencio SA for the year ended 30 September 2025. 1.779.647 shares of Ascencio SA were represented, or 27 % of the total number of shares in existence. Approval of the annual accounts of Ascencio SA and appropriation of profit The Meeting approved the distribution of a gross dividend of EUR 4.45 per share. The Meeting gave discharge, by separate vote, to the sole statut...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.